Femasys Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Femasys wird ein Gewinn- und Umsatzwachstum von 20.6% bzw. 62.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 40.4% pro Jahr wachsen soll.

Wichtige Informationen

20.6%

Wachstumsrate der Gewinne

40.4%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	62.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry?

Oct 31

Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now

Jul 05

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:FEMY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	18	-22	-15	N/A	2
12/31/2025	10	-19	-18	N/A	4
12/31/2024	3	-18	-10	N/A	4
9/30/2024	1	-18	-18	-17	N/A
6/30/2024	1	-17	-15	-15	N/A
3/31/2024	1	-15	-13	-13	N/A
12/31/2023	1	-14	-11	-11	N/A
9/30/2023	1	-13	-11	-11	N/A
6/30/2023	1	-12	-11	-11	N/A
3/31/2023	1	-11	-11	-11	N/A
12/31/2022	1	-11	-11	-11	N/A
9/30/2022	1	-11	-11	-10	N/A
6/30/2022	1	-10	-10	-9	N/A
3/31/2022	1	-9	-10	-10	N/A
12/31/2021	1	-8	-8	-8	N/A
9/30/2021	1	-7	-7	-7	N/A
6/30/2021	1	-6	-6	-6	N/A
3/31/2021	1	-7	-4	-4	N/A
12/31/2020	1	-7	-5	-5	N/A
12/31/2019	1	-11	-12	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: FEMY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: FEMY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: FEMY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: FEMYDie Einnahmen des Unternehmens (62.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: FEMYDie Einnahmen des Unternehmens (62.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von FEMY in 3 Jahren voraussichtlich hoch sein wird

Femasys Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 17%

Consensus revenue estimates fall by 40%

Consensus revenue estimates decrease by 17%, EPS upgraded

Price target increased by 8.1% to US$10.00

Consensus revenue estimates fall by 13%

Consensus revenue estimates fall by 11%

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 17%

Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry?

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec, an Innovative Diagnostic Solution for Fallopian Tube Check

Consensus revenue estimates fall by 40%

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now

Femasys Inc., Annual General Meeting, Jul 12, 2024

Consensus revenue estimates decrease by 17%, EPS upgraded

Price target increased by 8.1% to US$10.00

New major risk - Financial position

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 13%

Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

New major risk - Share price stability

Femasys Inc. Appoints Richard Spector as Chief Commercial Officer

Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women

Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors

Femasys Inc. Appoints Joshua Silverman as Director

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 11%

New major risk - Revenue and earnings growth

Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation

Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

New major risk - Revenue and earnings growth

Femasys Inc. Designates Daniel Currie as its Chief Operating Officer

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Femasys Inc. Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, A Non-Surgical Alternative for Women

Femasys Inc. Announces Management Changes

Femasys' FemCath Intrauterine Catheter Receives Product Approval in Canada

Femasys Receives a Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded

Femasys Inc., Annual General Meeting, Jun 21, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Inc.'s FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada

Consensus EPS estimates fall by 32%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

Femasys Inc. Reports Encouraging Promotional Launch of Femcerv At AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons

Femasys Inc. Completes Over 25% of its Targeted Enrollment in its FemaSeed De Novo Trial

Price target decreased to US$7.33

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Femasys Inc. Provides Strategic Update on FemaSeed Pivotal Trial Design to Expedite Clinical Program Advancement

Femasys Inc. Appoints Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs, Effective October 10, 2022

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

Femasys Inc. Announces Commercial Availability of FemCerv®

Femasys commercially launches Femcerv for cervical cancer screening

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M

Femasys Inc. Announces Board Changes

We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Femasys Inc. Appoints Dov Elefant to Chief Financial Officer, Effective February 28, 2022

Insufficient new directors

Femasys: Revolutionizing Female Reproduction

Independent Director recently bought US$172k worth of stock

Femasys Inc. has completed an IPO in the amount of $34.45 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite